In 2019, the Department of Health started providing the antiretroviral drug dolutegravir as part of HIV treatment in the public sector. Three years later, close to 3.2 million people in South Africa are taking dolutegravir every day. Even so, the rollout of dolutegravir hasn’t all been smooth sailing. Elri Voigt investigates how the massive undertaking of switching millions of people to a new drug has gone.
If South Africa is forced to go into a COVID-19 lockdown again, HIV support groups and adherence clubs should remain functional to make sure that everyone is supported, has regular access to information and treatment, and that people are motivated to adhere to treatment, argue Annah Maluleke and Solanga Milambo.
Two years after it was announced that the ARV dolutegravir would become part of standard first line HIV treatment in South Africa, it is finally reaching significant numbers of people. But new research about a worrying side-effect, weight gain (particularly in women), has muddied its otherwise stellar reputation.
A new antiretroviral medicine called dolutegravir is about to be introduced in the public healthcare system. Dr Tom Boyles outlines seven things people may want to consider before switching to the new drug.
By Marcus Low – Medical research findings are often sensationalised and overstated in the mainstream media. We debunk three cases of HIV-related misreporting that caught our eye in recent months.
